Sector consensus Intellia Therapeutics, Inc.
Equities
NTLA
US45826J1051
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.48 USD | -0.07% |
|
+2.74% | +50.06% |
| Mar. 06 | Nektar Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) | RE |
| Mar. 03 | Intellia Therapeutics Presents Longer-Term Clinical Data For Lonvoguran Ziclumeran | CI |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 25.29 | +87.44% | 21 | ||||||
| 675.78 | +31.22% | 23 | ||||||
| 408.2 | +31.82% | 26 | ||||||
| 257,416.67 | +28.9% | 24 | ||||||
| 232.25 | +38.79% | 20 | ||||||
| 133.7 | +38.65% | 20 | ||||||
| 250.55 | +22.91% | 16 | ||||||
| 500.08 | +1.33% | 12 | ||||||
| 71.85 | +11.99% | 14 | ||||||
| 97.6 | +29.84% | 23 | ||||||
| 121.82 | +12.9% | 7 | ||||||
| 629.24 | +99.04% | 17 | ||||||
| 73.64 | +32.58% | 11 | ||||||
| 197.5 | +12.44% | 14 | ||||||
| 55.46 | +35.64% | 14 | ||||||
| 132.08 | +23.66% | 13 | ||||||
| 75.43 | +75.66% | 14 | ||||||
| 37.34 | +20.03% | 12 | ||||||
| Average | 14,507.47 | +35.27% | 17 | ||||||
| Weighted average by Cap. | 27,270.33 | +31.49% | 19 |
- Stock Market
- Equities
- NTLA Stock
- Sector Intellia Therapeutics, Inc.
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
